Gilead

Recludix Pharma Announces the Appointment of Senior Executive Matthew S. Caldemeyer as Chief Business Officer

Retrieved on: 
Thursday, September 29, 2022
Kelley School of Business, Michigan State University, Blueprint, Array, Inflammation, Lymphoma, Inflammatory bowel disease, Signal, Company, Rheumatoid arthritis, Pharming, Atopic dermatitis, Business, Patient, Gilead, Cancer, STAT6, Indiana University, Protein, Amgen, Sutro Biopharma, SH2, Degenerative disease, SAN, GLOBE, Asthma, Eli Lilly and Company, Eli Lilly, Drug discovery, STAT, Pharmaceutical industry

Mr. Caldemeyer added, “Recludix’s drug discovery platform has been prolific. With several programs being advanced for oncology and inflammatory diseases, there are many opportunities for the company to transform treatment paradigms for these patients. I am delighted to join the Recludix team.”   About RecludixRecludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets. The company was founded by members of Blueprint Medicines’ founding scientific team and its management team includes industry veterans with a track record of success in the discovery, development and commercialization of multiple oncology drugs. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors. Recludix’s most advanced programs are focused on Signal Transducer and Activator of Transcription (STAT) proteins -- STAT3 and STAT6 -- where abnormal activation is found in numerous cancer types, such as multiple leukemias and lymphomas, as well as inflammatory diseases, such as rheumatoid arthritis, asthma, atopic dermatitis, inflammatory bowel disease, and others. The company is advancing three other programs to undisclosed targets that also play a significant role in both cancer and autoimmune diseases. For more information, please visit the company’s website at https://recludixpharma.com.

Key Points: 
  • SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging cancer and inflammatory disease targets, today announced the appointment of Matthew Caldemeyer as chief business officer.
  • We are excited to welcome Matt to our executive leadership team, said Nancy Whiting, Pharm.D., chief executive officer of Recludix.
  • He previously served as head of business development at Ambrx and as director of corporate strategy and business development at Array BioPharma.
  • From 2004 to 2011, Mr. Caldemeyer was at Eli Lilly and Company where he held positions in business development, finance and manufacturing.

Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY159

Retrieved on: 
Tuesday, September 20, 2022
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Therapy, PDAC, Safety, Immunosuppression, HNSCC, Sofinnova, Cytokine, Myelocyte, Immunotherapy, ADCC, NSCLC, Biomarker, Ovarian cancer, Colorectal cancer, Chemokine, Cancer, CRC, Pionýr, Patient, Tams, TREM2, Gilead, TREM1, Tumor-associated macrophage, TAM, Biology, Metastasis, Mab, TNBC, New Enterprise Associates, Head, Tumor microenvironment, Gilead Sciences, Research, Large-cell lung carcinoma, Pharmacokinetics, Myeloid tissue, Pembrolizumab, TME, Phosphorylation, Medical imaging, Pharmaceutical industry, Vaccine

In the Phase 1a dose escalation study, PY159 was well tolerated in doses up to 10 milligrams per kilogram and showed dose-proportional pharmacokinetics.

Key Points: 
  • In the Phase 1a dose escalation study, PY159 was well tolerated in doses up to 10 milligrams per kilogram and showed dose-proportional pharmacokinetics.
  • With these conclusions from Phase 1a, we are excited to begin this Phase 1b expansion study with leading clinical sites and investigators.
  • The multi-centered, US-based Phase 1a study evaluated the safety and tolerability of PY159 alone and in combination with pembrolizumab in multiple solid tumors and determined a recommended Phase 1b dose for expansion.
  • The Phase 1b study will evaluate PY159 administered alone and in combination with pembrolizumab in predefined tumor types.

EQS-News: NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly

Retrieved on: 
Monday, September 19, 2022
VZV, HCV, Time, Safety, Infection, Influenza, COVID-19, Monkeypox virus, NYSE, Risk, FDA, Food, Dengue fever, Kidney, Virus, Advertising, Catalent, IND, Keratitis, Company, Consultant, HIV, Hepatitis B virus, Monkeypox, HBV, Toxicology, Optimism, Bird, Patient, Remdesivir, Eye, Gilead, Technology, US FDA, CTLT, Drug development, Degenerative disease, US, NASDAQ, Shingles, Gilead Sciences, Research, Pharmacokinetics, Smallpox, EKC, Food and Drug Administration Amendments Act of 2007, Hepatitis C, Vaccine, Pharmaceutical industry, Sulfur, West Nile virus, Rabies

In response to that rapid spread, NanoViricides Inc. (NYSEAMERICAN: NNVC) wants to speed up the timeline on the development of its novel antiviral platform to treat the monkeypox virus.

Key Points: 
  • In response to that rapid spread, NanoViricides Inc. (NYSEAMERICAN: NNVC) wants to speed up the timeline on the development of its novel antiviral platform to treat the monkeypox virus.
  • Heres the companys plan for bringing its monkeypox drug development platform to clinical trials sooner.
  • Having already begun drug development of NV-387-T, its monkeypox drug candidate, NanoViricides reports that its optimistic it can speed up the process to move the antiviral into human clinical trials quickly.
  • NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy.

The Reunion Project Names Jeff Berry as First Executive Director

Retrieved on: 
Tuesday, September 13, 2022
Privacy, Corporation, Center, COVID-19, Awareness, Ageing, City, HIV, Empowerment, Survivor, Person, Survival, Head, Gilead, National, CDC, Centers for Disease Control and Prevention, Silver, Foreign policy, Taxi positional awareness, Gilead Sciences, AIDS, ViiV Healthcare, Education, TRP, Reunion, Vaccine, Pharmaceutical industry

CHICAGO, Sept. 13, 2022 /PRNewswire/ -- For the first time HIV long-term survivors are now included in the National HIV/AIDS Strategy. As the U.S. and Centers for Disease Control and Prevention (CDC) commemorate National HIV and Aging Awareness Day (#NHAAD) on September 18, the unique needs of long-term survivors require bold action and visionary leadership. The Reunion Project (TRP), the national alliance of HIV long-term survivors, today announced that Jeff Berry has joined as its first executive director, effective September 1. Berry, who has been living with HIV for over 35 years, previously served as chair of The Reunion Project's National Steering Committee.

Key Points: 
  • The Reunion Project (TRP), the national alliance of HIV long-term survivors, today announced that Jeff Berry has joined as its first executive director, effective September 1.
  • Berry, who has been living with HIV for over 35 years, previously served as chair of The Reunion Project's National Steering Committee.
  • Berry, who has 30 years of experience working in the non-profit and publishing world, is co-founder of The Reunion Project.
  • Since its inception, The Reunion Project has established itself as the national network of long-term survivors of HIV.

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September

Retrieved on: 
Wednesday, September 7, 2022
Gilead, HBV, NASDAQ, CD8, Lung, HIV, KRAS, GLOBE, Conference, Cancer, Investor, Prostate cancer, Arenavirus, Vaccine

Archived replays will be accessible for 30 days following each event.

Key Points: 
  • Archived replays will be accessible for 30 days following each event.
  • HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease.
  • HOOKIPAs replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ cell responses and pathogen-neutralizing antibodies.
  • In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead.

Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors

Retrieved on: 
Thursday, September 1, 2022
University, Gilead, Bristol Myers Squibb, Research, NASDAQ, ATTR, Board, AL, Executive, Senior, NGM, Kosan Biosciences, MBA, GLOBE, Partner, Leadership, Chiron Corporation, Biology, Board of directors, Biotechnology, Therapy, Neurodegeneration, Company, Chemical engineering, LLC, Business, Kite Pharma, Director, Chicago (franchise), Industry, Acquisition, Management, Northwestern University

With the appointment of Ms. Kim, Prothena will expand its Board to 10 directors.

Key Points: 
  • With the appointment of Ms. Kim, Prothena will expand its Board to 10 directors.
  • We welcome Ms. Kim to our Board and look forward to her many contributions.
  • After watching the strong execution of Prothena over the past years, Im excited to join the Board of Directors at this pivotal stage for the company.
  • Ms. Kim currently serves on the Board of Directors for A2 Biotherapeutics, Inc., ReCode Therapeutics, Inc., IconOVir Bio, Inc., Aktis Oncology, PACT Pharma, Protego Therapeutics, and InduPro Labs.

Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum

Retrieved on: 
Thursday, September 1, 2022
Gilead, The Company, COVID-19, University, XDR, Pharmaceutical Development and Technology, Central nervous system, Therapy, Bachelor of Science in Human Biology, Infection, Board, Independent, Executive, Vulnerability and Risk Committee, CMC, Gilead Sciences, Chemistry, Medication, Multimedia, Malaria, Data science, HIV, Hepatitis B, National Taiwan University, National academy, Leadership, National Academy of Engineering, Board of directors, Company, Doctor of Philosophy, Syntex, Gedeon Richter (company), Risk, Industry, CNS, MDR, Patient, Pharmaceutical industry, Management

DURHAM, N.C. and BEIJING, Aug. 31, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced the appointment of healthcare industry veteran Taiyin Yang, Ph.D., to the Company's Board of Directors as co-chair of the newly expanded Audit and Risk Committee, effective September 1, 2022.

Key Points: 
  • Dr. Bouchon will continue to work with Brii Bio as an advisor to the Chairman and Chief Executive Officer.
  • "We're pleased to welcome Taiyin, an industry giant and admired leader, to our Board of Directors.
  • Her extensive industry experience within product development and commercial manufacturing will provide important synergies as we continue the accelerated corporate growth.
  • Dr. Yang also serves on the board of directors of Kodiak Sciences and Kronos Bio.

Change the Pattern: Sections of the AIDS Memorial Quilt Honoring Black and Brown Lives Lost to AIDS will Travel throughout the South in the Fight to End the Epidemic

Retrieved on: 
Monday, August 22, 2022
Statistics, Transgender, National AIDS Trust, Gilead, National, CEO, Corporation, AIDS, Pain, Program, Government, Awareness, Poverty, Man, HIV/AIDS, Racism, NAMES Project AIDS Memorial Quilt, Learning, Homophobia, Gilead Sciences, Organization, HIV, Changing rainfall patterns since the 1970s in Rift Valley, Kenya, GLOBE, History, Population, Black Box (Brown Eyed Girls album), Social justice, Name, Woman, Health, Love, SOS, Â, Sewing, Pharmaceutical industry, Quilt, Pattern, Black

Partnering with Southern AIDS Coalition, the multi-city initiative will address opportunities to take action and support communities in the fight to end the southern epidemic.

Key Points: 
  • Partnering with Southern AIDS Coalition, the multi-city initiative will address opportunities to take action and support communities in the fight to end the southern epidemic.
  • It will be the largest display of the AIDS Memorial Quilt ever in the state.
  • This meeting of devoted friends, lovers and activists would serve as the foundation for The NAMES Projects AIDS Memorial Quilt.
  • They saw the Quilt as an activist tool to push the government into taking action to end the epidemic.

HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates

Retrieved on: 
Thursday, August 11, 2022
FDA, Gilead, Prostate cancer, Association, State Administrative Expenses, ASCO, American Association, GLOBE, Senior, NEW, Drug, Annual general meeting, Growth, Cancer, Food and Drug Administration, Arenavirus, Society, American Society of Clinical Oncology, Patient, Pembrolizumab, Company, Research and development, Collaboration, Viral load, NASDAQ, AACR, Head, US, American Association for Cancer Research, US Foods, Development, Administration, Food, Drug Master File, Pharmaceutical industry, Vaccine, Health insurance, Lease, Research

In July, HOOKIPA announced that the US FDA accepted HOOKIPAs Investigational New Drug Application for HB-300 forthe treatment of metastatic castration-resistant prostate cancer.

Key Points: 
  • In July, HOOKIPA announced that the US FDA accepted HOOKIPAs Investigational New Drug Application for HB-300 forthe treatment of metastatic castration-resistant prostate cancer.
  • A Drug Master File was also accepted, facilitating reduced cycle time between completion of preclinical studies and clinical entry of HOOKIPAs pipeline projects.
  • Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapy.
  • In June, HOOKIPA presented preclinical data on its novel arenaviral HIV therapeutic vaccines.

DGAP-News: Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution

Retrieved on: 
Wednesday, August 10, 2022
Survival, Poxviridae, Research, Molluscum contagiosum, Fever, Patient, Family, Hepatitis C, Influenza, Hepatitis B virus, US, Monkeypox virus, Animal, Degenerative disease, Smallpox, Dengue fever, Travel, Technology, Fear, Kidney, DNA, Safety, EKC, Ulcer, DNA virus, Remdesivir, Monkeypox, Smallpox vaccine, Virus, Simplex, HBV, Pox, SIGA Technologies, US FDA, Rash, COVID-19, Bioterrorism, Drug development, Vaccination, Disease, HIV, HCV, Time, Keratitis, Advertising, FDA, Bird, VZV, NYSE, Population, Shingles, IND, Company, Lymph, Eye, NASDAQ, Human, Consultant, Gilead, Pharmaceutical industry, Vaccine, Rabies, West Nile virus, Central Africa

However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX.

Key Points: 
  • However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX.
  • It had shown effectiveness in monkeys to increase survival upon monkeypox virus infection.
  • Thus there is a clear and immediate need for rapid new drug development against monkeypox virus and potential variants.
  • During the smallpox eradication program in the late 1960s, the vaccine used to prevent smallpox also helped curb monkeypox infections.